TokenPost·
BioNTech to Evaluate Pumitamig With Gilead’s Trodelvy
The companies are examining the combination as an initial treatment for triple-negative breast cancer with low or absent PD-L1 expression.
More news
- TokenPostMemeCore Rises 25.65% to Lead Gains Among Top 90 Cryptocurrencies
- TokenPostMason Versluis Puts $5.89 XRP Expectation in Bull-Run Post
- TokenPostWOO Network Token (WOO) Rose 12.63% in Five Minutes to $0.01195
- TokenPostUber Shares Fall 3.43% Friday, Extending Five-Session Loss to 5.19%
- TokenPostEnergy Transfer Units Rise 2.05% Friday to Close at $20.45
- TokenPostLazio Calls for U.S. Auto Incentives as China Produced 16 Million EVs in 2025